Nutritional support of pediatric patients with cancer consuming an enteral formula with fructooligosaccharides

Shan Zheng, Philippe Steenhout, Dong Kuiran, Qihong Wang, Wang Weiping, Corinne Hager, Ferdinand Haschke, Roger A. Clemens

Research output: Contribution to journalArticle

Abstract

The objective of this study was to determine the tolerance and effects of a fructooligosaccharide (FOS)-containing enteral formula on fecal microbiota, nutritional status, biologic and immunologic outcomes of pediatric patients with cancer. A prospective, randomized, double-blinded, controlled trial was conducted at Children's Hospital, Shanghai Medical University. Sixty-seven hospitalized patients (1-12 years old) diagnosed with cancer (stage 1-3) and undergoing chemotherapy met study inclusion criteria. Patients received at least 400 mL of an assigned formula for 13 to 30 days. The control group received enteral formula without FOS (control); the study group received the same formula with FOS (+FOS; 2 g/L). Stool samples on days 0, 3, 13, and 30 were analyzed for bifidobacteria, lactobacilli, and other microbiota. Biochemical markers of nutritional and hematologic status and anthropometrics were also assessed. The mean energy intake provided by the formulas was similar. At day 30 but not day 13, stool lactobacilli counts were significantly (P <.02) higher in the +FOS group. A similar trend was seen for bifidobacteria. There were no clinically significant differences between groups for nutritional or hematologic status. There were no differences in immunologic parameters assessed except for significantly higher α1-acid glycoprotein in the control at day 13 (P <.01). The prognostic inflammatory and nutritional index of +FOS at day 30 significantly decreased compared with control (P = .016). These data suggest that an enteral formula containing dietary FOS produced a mild prebiotic effect at day 30 without any gastrointestinal discomfort in pediatric patients with cancer. Both enteral formulas were well-tolerated and accepted.

Original languageEnglish (US)
Pages (from-to)154-162
Number of pages9
JournalNutrition Research
Volume26
Issue number4
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Nutritional Support
Small Intestine
Pediatrics
Neoplasms
Bifidobacterium
Microbiota
Lactobacillus
Nutritional Status
Prebiotics
Nutrition Assessment
fructooligosaccharide
Energy Intake
Glycoproteins
Biomarkers
Drug Therapy
Control Groups
Acids

Keywords

  • Bifidobacteria
  • Cancer
  • Fructooligosaccharides
  • Tolerance

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Nutritional support of pediatric patients with cancer consuming an enteral formula with fructooligosaccharides. / Zheng, Shan; Steenhout, Philippe; Kuiran, Dong; Wang, Qihong; Weiping, Wang; Hager, Corinne; Haschke, Ferdinand; Clemens, Roger A.

In: Nutrition Research, Vol. 26, No. 4, 04.2006, p. 154-162.

Research output: Contribution to journalArticle

Zheng, S, Steenhout, P, Kuiran, D, Wang, Q, Weiping, W, Hager, C, Haschke, F & Clemens, RA 2006, 'Nutritional support of pediatric patients with cancer consuming an enteral formula with fructooligosaccharides', Nutrition Research, vol. 26, no. 4, pp. 154-162. https://doi.org/10.1016/j.nutres.2006.04.001
Zheng, Shan ; Steenhout, Philippe ; Kuiran, Dong ; Wang, Qihong ; Weiping, Wang ; Hager, Corinne ; Haschke, Ferdinand ; Clemens, Roger A. / Nutritional support of pediatric patients with cancer consuming an enteral formula with fructooligosaccharides. In: Nutrition Research. 2006 ; Vol. 26, No. 4. pp. 154-162.
@article{8d315b3697b64cc8966cdd53dafd0a53,
title = "Nutritional support of pediatric patients with cancer consuming an enteral formula with fructooligosaccharides",
abstract = "The objective of this study was to determine the tolerance and effects of a fructooligosaccharide (FOS)-containing enteral formula on fecal microbiota, nutritional status, biologic and immunologic outcomes of pediatric patients with cancer. A prospective, randomized, double-blinded, controlled trial was conducted at Children's Hospital, Shanghai Medical University. Sixty-seven hospitalized patients (1-12 years old) diagnosed with cancer (stage 1-3) and undergoing chemotherapy met study inclusion criteria. Patients received at least 400 mL of an assigned formula for 13 to 30 days. The control group received enteral formula without FOS (control); the study group received the same formula with FOS (+FOS; 2 g/L). Stool samples on days 0, 3, 13, and 30 were analyzed for bifidobacteria, lactobacilli, and other microbiota. Biochemical markers of nutritional and hematologic status and anthropometrics were also assessed. The mean energy intake provided by the formulas was similar. At day 30 but not day 13, stool lactobacilli counts were significantly (P <.02) higher in the +FOS group. A similar trend was seen for bifidobacteria. There were no clinically significant differences between groups for nutritional or hematologic status. There were no differences in immunologic parameters assessed except for significantly higher α1-acid glycoprotein in the control at day 13 (P <.01). The prognostic inflammatory and nutritional index of +FOS at day 30 significantly decreased compared with control (P = .016). These data suggest that an enteral formula containing dietary FOS produced a mild prebiotic effect at day 30 without any gastrointestinal discomfort in pediatric patients with cancer. Both enteral formulas were well-tolerated and accepted.",
keywords = "Bifidobacteria, Cancer, Fructooligosaccharides, Tolerance",
author = "Shan Zheng and Philippe Steenhout and Dong Kuiran and Qihong Wang and Wang Weiping and Corinne Hager and Ferdinand Haschke and Clemens, {Roger A.}",
year = "2006",
month = "4",
doi = "10.1016/j.nutres.2006.04.001",
language = "English (US)",
volume = "26",
pages = "154--162",
journal = "Nutrition Research",
issn = "0271-5317",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Nutritional support of pediatric patients with cancer consuming an enteral formula with fructooligosaccharides

AU - Zheng, Shan

AU - Steenhout, Philippe

AU - Kuiran, Dong

AU - Wang, Qihong

AU - Weiping, Wang

AU - Hager, Corinne

AU - Haschke, Ferdinand

AU - Clemens, Roger A.

PY - 2006/4

Y1 - 2006/4

N2 - The objective of this study was to determine the tolerance and effects of a fructooligosaccharide (FOS)-containing enteral formula on fecal microbiota, nutritional status, biologic and immunologic outcomes of pediatric patients with cancer. A prospective, randomized, double-blinded, controlled trial was conducted at Children's Hospital, Shanghai Medical University. Sixty-seven hospitalized patients (1-12 years old) diagnosed with cancer (stage 1-3) and undergoing chemotherapy met study inclusion criteria. Patients received at least 400 mL of an assigned formula for 13 to 30 days. The control group received enteral formula without FOS (control); the study group received the same formula with FOS (+FOS; 2 g/L). Stool samples on days 0, 3, 13, and 30 were analyzed for bifidobacteria, lactobacilli, and other microbiota. Biochemical markers of nutritional and hematologic status and anthropometrics were also assessed. The mean energy intake provided by the formulas was similar. At day 30 but not day 13, stool lactobacilli counts were significantly (P <.02) higher in the +FOS group. A similar trend was seen for bifidobacteria. There were no clinically significant differences between groups for nutritional or hematologic status. There were no differences in immunologic parameters assessed except for significantly higher α1-acid glycoprotein in the control at day 13 (P <.01). The prognostic inflammatory and nutritional index of +FOS at day 30 significantly decreased compared with control (P = .016). These data suggest that an enteral formula containing dietary FOS produced a mild prebiotic effect at day 30 without any gastrointestinal discomfort in pediatric patients with cancer. Both enteral formulas were well-tolerated and accepted.

AB - The objective of this study was to determine the tolerance and effects of a fructooligosaccharide (FOS)-containing enteral formula on fecal microbiota, nutritional status, biologic and immunologic outcomes of pediatric patients with cancer. A prospective, randomized, double-blinded, controlled trial was conducted at Children's Hospital, Shanghai Medical University. Sixty-seven hospitalized patients (1-12 years old) diagnosed with cancer (stage 1-3) and undergoing chemotherapy met study inclusion criteria. Patients received at least 400 mL of an assigned formula for 13 to 30 days. The control group received enteral formula without FOS (control); the study group received the same formula with FOS (+FOS; 2 g/L). Stool samples on days 0, 3, 13, and 30 were analyzed for bifidobacteria, lactobacilli, and other microbiota. Biochemical markers of nutritional and hematologic status and anthropometrics were also assessed. The mean energy intake provided by the formulas was similar. At day 30 but not day 13, stool lactobacilli counts were significantly (P <.02) higher in the +FOS group. A similar trend was seen for bifidobacteria. There were no clinically significant differences between groups for nutritional or hematologic status. There were no differences in immunologic parameters assessed except for significantly higher α1-acid glycoprotein in the control at day 13 (P <.01). The prognostic inflammatory and nutritional index of +FOS at day 30 significantly decreased compared with control (P = .016). These data suggest that an enteral formula containing dietary FOS produced a mild prebiotic effect at day 30 without any gastrointestinal discomfort in pediatric patients with cancer. Both enteral formulas were well-tolerated and accepted.

KW - Bifidobacteria

KW - Cancer

KW - Fructooligosaccharides

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=33744786252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744786252&partnerID=8YFLogxK

U2 - 10.1016/j.nutres.2006.04.001

DO - 10.1016/j.nutres.2006.04.001

M3 - Article

AN - SCOPUS:33744786252

VL - 26

SP - 154

EP - 162

JO - Nutrition Research

JF - Nutrition Research

SN - 0271-5317

IS - 4

ER -